Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Mayers

Showing results (61-70 of 91) with videos related to

Pageof 10
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 29, 2000
Primary lamivudine resistance in acute/early human immunodeficiency virus infectionB Conway, V Montessori, D Rouleau, et al.
Antimicrobial Agents and Chemotherapy|May 1, 1995
Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolatesJ W Mellors, H Z Bazmi, R F Schinazi, et al.
Joint Commission Journal on Quality and Patient Safety|May 16, 2018
1,300 Days and Counting: A Risk Model Approach to Preventing Retained Foreign Objects (RFOs)Erika G Duggan, Jimmy Fernandez, Mary May Saulan, et al.
AIDS Research and Human Retroviruses|December 7, 2006
Seeking ethical designs for HIV clinical trials in treatment-experienced patients: an industry perspectiveDouglas L Mayers, Jain Chung, Veronika M Kohlbrenner, et al.
Journal of Virology|August 25, 2006
Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavirJohn D Baxter, Jonathan M Schapiro, Charles A B Boucher, et al.
Biochemistry|May 9, 1972
Synthesis of poly -glutamyl- -aminobutyric acids and their reactivity with antiserum against Bacillus anthracis polypeptideJ Kovacs, A Kapoor, U R Ghatak, et al.
The Journal of Infectious Diseases|October 1, 1995
Quantitative relationship of circulating p24 antigen with human immunodeficiency virus (HIV) RNA and specific antibody in HIV-infected subjects receiving antiretroviral therapy. The RV43 Study GroupA E Brown, M T Vahey, S Y Zhou, et al.
The Journal of Bone and Joint Surgery. American Volume|October 27, 2001
Use of fibrin sealant to reduce bloody drainage and hemoglobin loss after total knee arthroplasty: a brief note on a randomized prospective trialG J Wang, D S Hungerford, C G Savory, et al.
JAMA|December 8, 1989
Incidence of human immunodeficiency virus seroconversion in US Navy and Marine Corps personnel, 1986 through 1988F C Garland, D L Mayers, T M Hickey, et al.
Journal of Viral Hepatitis|October 6, 2022
A randomized phase 1b trial of the active site polymerase inhibitor nucleotide ATI-2173 in patients with chronic hepatitis B virus infectionKatherine E Squires, Lauren Ogilvie, Alina Jucov, et al.
Pageof 10

Showing results (61-70 of 91) with videos related to

Sort By:
Pageof 10
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 29, 2000
Primary lamivudine resistance in acute/early human immunodeficiency virus infectionB Conway, V Montessori, D Rouleau, et al.
Antimicrobial Agents and Chemotherapy|May 1, 1995
Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolatesJ W Mellors, H Z Bazmi, R F Schinazi, et al.
Joint Commission Journal on Quality and Patient Safety|May 16, 2018
1,300 Days and Counting: A Risk Model Approach to Preventing Retained Foreign Objects (RFOs)Erika G Duggan, Jimmy Fernandez, Mary May Saulan, et al.
AIDS Research and Human Retroviruses|December 7, 2006
Seeking ethical designs for HIV clinical trials in treatment-experienced patients: an industry perspectiveDouglas L Mayers, Jain Chung, Veronika M Kohlbrenner, et al.
Journal of Virology|August 25, 2006
Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavirJohn D Baxter, Jonathan M Schapiro, Charles A B Boucher, et al.
Biochemistry|May 9, 1972
Synthesis of poly -glutamyl- -aminobutyric acids and their reactivity with antiserum against Bacillus anthracis polypeptideJ Kovacs, A Kapoor, U R Ghatak, et al.
The Journal of Infectious Diseases|October 1, 1995
Quantitative relationship of circulating p24 antigen with human immunodeficiency virus (HIV) RNA and specific antibody in HIV-infected subjects receiving antiretroviral therapy. The RV43 Study GroupA E Brown, M T Vahey, S Y Zhou, et al.
The Journal of Bone and Joint Surgery. American Volume|October 27, 2001
Use of fibrin sealant to reduce bloody drainage and hemoglobin loss after total knee arthroplasty: a brief note on a randomized prospective trialG J Wang, D S Hungerford, C G Savory, et al.
JAMA|December 8, 1989
Incidence of human immunodeficiency virus seroconversion in US Navy and Marine Corps personnel, 1986 through 1988F C Garland, D L Mayers, T M Hickey, et al.
Journal of Viral Hepatitis|October 6, 2022
A randomized phase 1b trial of the active site polymerase inhibitor nucleotide ATI-2173 in patients with chronic hepatitis B virus infectionKatherine E Squires, Lauren Ogilvie, Alina Jucov, et al.
Pageof 10